Australia’s Fortescue stops use of voluntary carbon offsets

Fortescue Metals Group, one of the world’s largest iron ore producers and a significant emitter of greenhouse gases, has taken a bold step by announcing the cessation of its use of voluntary carbon offsets. This move sets Fortescue apart as the only heavy emitter globally to halt the procurement of these offsets. The decision has come amid mounting questions about the efficacy and authenticity of voluntary carbon offsets in achieving substantial reductions in emissions. The annual report published by the mining giant last month highlighted the challenges related to the quality and impact of voluntary carbon offset programs.

In the 12 months leading up to June 30, Fortescue generated a substantial 2.55 million tons of scope 1 and 2 carbon dioxide pollution. The company confirmed that it has commenced implementing a policy to cease purchasing credits from this financial year onwards.

Notably, Fortescue spent $6.2 million in the fiscal year 2023 on voluntary offsets and surrendered a total of 336,833 tons of credits. The voluntary carbon market, despite growing scrutiny and doubts about its effectiveness, is predicted to expand significantly, potentially reaching as high as $953 billion by 2037, according to BloombergNEF.

Fortescue has set ambitious environmental targets, aiming to eliminate scope 1 and 2 emissions (those directly linked to a company’s operations) by 2030.

Additionally, the company aims to phase out the use of fossil fuels at its Australian iron ore sites. These objectives are in line with the emission reduction goals of some of Australia’s major energy producers, such as the local units of Shell Plc and Exxon Mobil Corp.

Despite being a major player in the iron ore industry, Fortescue’s decision to forego voluntary carbon offsets demonstrates a commitment to finding more direct and effective ways to reduce its carbon footprint and contribute to the fight against climate change.

By QUATRO Strategies International Inc.

QUATRO Strategies International Inc. is the leading business insights and corporate strategy company based in Toronto, Ontario. Through our unique services, we counsel our clients on their key strategic issues, leveraging our deep industry expertise and using analytical rigor to help them make informed decisions to establish a competitive edge in the marketplace.

Elevate your business with QU4TRO PRO!

Gain access to comprehensive analysis, in-depth reports and market trends.

Interested in learning more?

Sign up for Top Insights Today

Top Insights Today delivers the latest insights straight to your inbox.

You will get daily industry insights on

Oil & Gas, Rare Earths & Commodities, Mining & Metals, EVs & Battery Technology, ESG & Renewable Energy, AI & Semiconductors, Aerospace & Defense, Sanctions & Regulation, Business & Politics.

By clicking subscribe you agree to our privacy and cookie policy and terms and conditions of use.

Read more insights

France in talks with Renault to boost drone production for Ukraine

France’s defense ministry has initiated talks with Renault to explore the automaker’s potential role in manufacturing drones, the company confirmed on Sunday, marking a notable convergence of civilian industry and defense policy amid the ongoing war in Ukraine.

The outreach follows comments from French Defence Minister Sébastien Lecornu, who last week announced plans to partner a major French automaker with a smaller defense contractor to help build drones in Ukraine. Although Lecornu did not name the companies involved, Renault was expected to play that role. Renault acknowledged it had been approached but said the discussions remain preliminary and contingent on further details from the ministry.

India eyes new pharma markets to hedge against U.S. trade risks

India is preparing to expand its pharmaceutical export footprint beyond its traditional reliance on the United States, seeking new growth in Russia, the Netherlands, Brazil, and other European markets. The move comes as New Delhi quietly braces for the possibility that its drug exports could eventually be caught in the crossfire of U.S. President Donald Trump’s aggressive tariff regime, despite pharmaceuticals being exempt so far.

The U.S. has long been India’s most critical market, accounting for more than one-third of total exports. Indian firms dominate the U.S. generic drugs segment, supplying affordable versions of widely used medicines, which generated roughly $10.5 billion in fiscal 2025 alone, up 20% from the previous year. Yet the uncertainty hanging over U.S.-India trade relations has prompted policymakers and industry leaders to accelerate efforts to diversify.

U.S. to close loophole that allows Chinese companies have access to American AI chips

The Biden administration is considering taking steps to close a significant loophole that allows Chinese companies to gain access to American artificial intelligence (AI) chips through their units located overseas. This development follows the imposition of restrictions by the U.S. last year on shipments…

Stay informed

error: Content is protected !!